Position in UTHR
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$552,124
+$259,785 QoQ
Shares Held
1,019
+106.7% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#555
of 870 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in UTHR Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Snowden Capital Advisors LLC holds $4,377,396 across 7 Drug Manufacturers - Specialty & Generic names. UTHR ranks #3 (12.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TEVA |
Teva Pharmaceutical Industries Ltd
|
63,441 | $2,149,381 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
5,428 | $914,835 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
This page
|
1,019 | $552,124 | |
| 4 | ZTS |
Zoetis Inc.
|
6,658 | $478,443 | |
| 5 | HLN |
Haleon plc
|
17,835 | $166,400 | |
| 6 | EVO |
Evotec SE
|
25,379 | $71,061 | |
| 7 | AQST |
Aquestive Therapeutics, Inc.
|
10,854 | $45,152 |
All Filings in UTHR
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $552,124 | 1,019 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $292,339 | 493 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $251,421 | 516 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||